ステムリムの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2023/06/21 | 1,064 | 1,088 | 1,048 | 1,080 | +20 | +1.9% | 581,700 |
2023/06/20 | 1,064 | 1,070 | 1,030 | 1,060 | -7 | -0.7% | 582,800 |
2023/06/19 | 1,018 | 1,100 | 1,006 | 1,067 | +58 | +5.7% | 908,200 |
2023/06/16 | 977 | 1,037 | 975 | 1,009 | +44 | +4.6% | 923,700 |
2023/06/15 | 1,032 | 1,043 | 961 | 965 | -27 | -2.7% | 1,513,100 |
2023/06/14 | 1,013 | 1,013 | 989 | 992 | -16 | -1.6% | 452,800 |
2023/06/13 | 1,018 | 1,018 | 996 | 1,008 | -6 | -0.6% | 340,000 |
2023/06/12 | 990 | 1,016 | 970 | 1,014 | +21 | +2.1% | 380,800 |
2023/06/09 | 996 | 1,007 | 977 | 993 | +9 | +0.9% | 449,700 |
2023/06/08 | 1,040 | 1,046 | 979 | 984 | -51 | -4.9% | 904,900 |
2023/06/07 | 1,021 | 1,052 | 1,013 | 1,035 | +14 | +1.4% | 393,100 |
2023/06/06 | 1,034 | 1,034 | 1,001 | 1,021 | -11 | -1.1% | 340,200 |
2023/06/05 | 1,038 | 1,043 | 1,018 | 1,032 | ±0 | ±0% | 257,100 |
2023/06/02 | 1,020 | 1,034 | 1,008 | 1,032 | +8 | +0.8% | 307,100 |
2023/06/01 | 1,023 | 1,040 | 1,017 | 1,024 | -2 | -0.2% | 241,900 |
2023/05/31 | 1,036 | 1,065 | 1,013 | 1,026 | -6 | -0.6% | 1,051,700 |
2023/05/30 | 1,027 | 1,050 | 1,019 | 1,032 | +10 | +1% | 274,300 |
2023/05/29 | 1,033 | 1,033 | 1,010 | 1,022 | +15 | +1.5% | 342,000 |
2023/05/26 | 1,043 | 1,047 | 994 | 1,007 | -58 | -5.4% | 1,094,200 |
2023/05/25 | 1,146 | 1,148 | 1,060 | 1,065 | -67 | -5.9% | 775,200 |
2023/05/24 | 1,110 | 1,175 | 1,099 | 1,132 | +2 | +0.2% | 832,000 |
2023/05/23 | 1,193 | 1,205 | 1,121 | 1,130 | -6 | -0.5% | 576,100 |
2023/05/22 | 1,139 | 1,154 | 1,130 | 1,136 | -16 | -1.4% | 312,400 |
2023/05/19 | 1,167 | 1,169 | 1,137 | 1,152 | -16 | -1.4% | 335,300 |
2023/05/18 | 1,193 | 1,200 | 1,168 | 1,168 | -17 | -1.4% | 262,600 |
2023/05/17 | 1,197 | 1,201 | 1,175 | 1,185 | -17 | -1.4% | 294,100 |
2023/05/16 | 1,180 | 1,209 | 1,165 | 1,202 | +26 | +2.2% | 386,800 |
2023/05/15 | 1,166 | 1,180 | 1,153 | 1,176 | -1 | -0.1% | 379,900 |
2023/05/12 | 1,230 | 1,236 | 1,161 | 1,177 | -68 | -5.5% | 700,100 |
2023/05/11 | 1,278 | 1,282 | 1,231 | 1,245 | -27 | -2.1% | 313,700 |
2023/05/10 | 1,284 | 1,295 | 1,265 | 1,272 | -16 | -1.2% | 193,300 |
2023/05/09 | 1,280 | 1,311 | 1,278 | 1,288 | +5 | +0.4% | 293,300 |
2023/05/08 | 1,260 | 1,304 | 1,254 | 1,283 | +29 | +2.3% | 300,400 |
2023/05/02 | 1,272 | 1,294 | 1,251 | 1,254 | -27 | -2.1% | 241,700 |
2023/05/01 | 1,234 | 1,301 | 1,231 | 1,281 | +29 | +2.3% | 340,900 |
2023/04/28 | 1,280 | 1,298 | 1,246 | 1,252 | -41 | -3.2% | 389,500 |
2023/04/27 | 1,310 | 1,312 | 1,267 | 1,293 | -2 | -0.2% | 290,800 |
2023/04/26 | 1,305 | 1,308 | 1,260 | 1,295 | -5 | -0.4% | 408,700 |
2023/04/25 | 1,283 | 1,320 | 1,280 | 1,300 | +30 | +2.4% | 349,900 |
2023/04/24 | 1,245 | 1,290 | 1,238 | 1,270 | +12 | +1% | 460,100 |
2023/04/21 | 1,308 | 1,315 | 1,250 | 1,258 | -45 | -3.5% | 777,800 |
2023/04/20 | 1,350 | 1,362 | 1,303 | 1,303 | -42 | -3.1% | 486,700 |
2023/04/19 | 1,334 | 1,360 | 1,307 | 1,345 | +3 | +0.2% | 596,700 |
2023/04/18 | 1,371 | 1,399 | 1,330 | 1,342 | -43 | -3.1% | 748,700 |
2023/04/17 | 1,364 | 1,429 | 1,354 | 1,385 | +5 | +0.4% | 779,900 |
2023/04/14 | 1,371 | 1,426 | 1,362 | 1,380 | -21 | -1.5% | 1,347,400 |
2023/04/13 | 1,435 | 1,518 | 1,367 | 1,401 | +80 | +6.1% | 5,233,500 |
2023/04/12 | 1,290 | 1,365 | 1,280 | 1,321 | +2 | +0.2% | 3,669,200 |
2023/04/11 | 1,318 | 1,319 | 1,225 | 1,319 | +300 | +29.4% | 3,459,100 |
2023/04/10 | 1,025 | 1,048 | 1,016 | 1,019 | -6 | -0.6% | 205,400 |
351~
400
件表示中 / 1293件
類似銘柄と比較する
現在ご覧いただいている「ステムリム」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
ステムリム | 35,800円 | - | - | 0.00% | - | 2.91倍 |
|
大阪大学発バイオベンチャー。損傷細胞の活性化物質を動員、再生を促す「再生誘導医薬」を開発 |
扶桑薬 | 266,000円 | +8.3% | +98.1% | 3.08% | 8.74倍 | 0.60倍 |
|
人工腎臓用透析剤・補液が主軸の製薬中堅、透析剤は国内シェア5割。後発薬や製造受託も展開 |
セルソース | 111,700円 | -3.0% | -55.9% | 0.45% | 53.06倍 | 3.66倍 |
|
脂肪・血液由来の細胞加工受託など再生医療、変形性ひざ関節症向け軸に不妊治療関連も展開 |
大幸薬品 | 36,400円 | +11.1% | - | 0.00% | 33.21倍 | 2.26倍 |
|
止瀉薬「正露丸」で有名な大衆薬中堅。オーナー経営色。不振の「クレベリン」など事業再構築中 |
ヘリオス | 19,600円 | +395.9% | - | 0.00% | - | 5.45倍 |
|
iPS細胞、体性幹細胞を活用する再生医薬品バイオベンチャー。住友ファーマと共同開発も |
市場注目の銘柄
チャート関連のコラム